MFIMFI
EGRX

Mesirow Financial Investment Management - Fixed Income’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Mesirow Financial Investment Management - Fixed Income’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2,910
Closed -$231K – 248
2016
Q4 		$231K Sell
2,910
-260
-8% -$18.9K 0.01% 219
2016
Q3 		$222K Buy
+3,170
New +$176K 0.01% 219

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Mesirow Financial Investment Management - Fixed Income's EGRX Position: Q1 2017 in Review

Mesirow Financial Investment Management - Fixed Income sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2017, closing a stake of 2,910 shares — an estimated $231K sold.

Mesirow Financial Investment Management - Fixed Income first reported a position in EGRX in Q3 2016 and held it in 2 quarters. The position peaked at $231K in Q4 2016. 147 funds tracked by Wall St. Rank hold EGRX as of Q1 2017.

  • Mesirow Financial Investment Management - Fixed Income reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Mesirow Financial Investment Management - Fixed Income sold 2,910 Eagle Pharmaceuticals, Inc. shares in Q1 2017, an estimated $231K.
  • Mesirow Financial Investment Management - Fixed Income first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2016 and held it in 2 quarters.
  • Mesirow Financial Investment Management - Fixed Income's Eagle Pharmaceuticals, Inc. position peaked at $231K in Q4 2016.
  • 147 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2017.

Based on Mesirow Financial Investment Management - Fixed Income's 13F filing for Q1 2017, filed 25 Apr 2017.